APPENDIX A

Publication

- Ching Chin Lee, Fatimah Harun, Muhammad Yazid Jalaludin, Choon Han Heh, Rozana Othman, and Sarni Mat Junit, A novel, homozygous c.1502T>G (p.Val501Gly) mutation in the *thyroid peroxidase* gene in Malaysian Sisters with congenital hypothyroidism and multinodular goiter, International Journal of Endocrinology, vol. 2013, Article ID 987186, 7 pages, 2013. doi:10.1155/2013/987186 (*ISI-Cited Publication*)
- Ching-Chin Lee, Muhammad-Yazid Jalaludin, Fatimah Harun, Chor-Yin Lim, Khoon-Leong Ng and Sarni Mat-Junit. Functional analyses of c.2268dup in *TPO* gene associated with goitrous congenital hypothyroidism (Journal of Molecular Endocrinology: Submitted)

APPENDIX B

List of posters presented in this study

- Lee Ching Chin, Fatimah Harun, Muhammad Yazid Jalaludin and Sarni Mat Junit. Nonsense-associated alternative splicing in exon 13 of *thyroid peroxidase* gene (*TPO*) as a consequence of a common c.2268dup mutation in Chinese patients with thyroid dyshormonogenesis. Proc. 36th Annual Conference of Malaysian Society for Biochemistry and Molecular Biology, Kuala Lumpur (2011), p83. (*Non-ISI/Non-SCOPUS Cited Publication*)
- Muhammad Yazid Jalaludin, Lim Song Hai, Lee Ching Chin, Fatimah Harun, and Sarni Mat Junit. Follicular adenoma in goitrousc hypothyroidism due to *thyroid peroxidase* gene mutation in a Chinese patient. Proc. 50th Annual European Society for Paediatric Endocrinology Meeting, Glasgow (2011). (Accepted, *ISI Cited Publication*)
- Lee Ching Chin, Kang In Nee, Fatimah Harun, Muhammad Yazid Jalaludin and Sarni Mat Junit. Characterisation of the human *thyroid peroxidase* gene mutation(s) in patients presented with congenital hypothyroidism, dyshormonogenesis and goiter. Proc. 35th Annual Conference of the Malaysian Society for Biochemistry and Molecular Biology, Kuala Lumpur,(2010), p80. (*Non-ISI/Non-SCOPUS Cited Publication*)

The published sequence of the:

1) Human thyroid peroxidase (TPO), transcript variant 1, mRNA (NCBI

Reference Sequence: NM_000547.5)

start codon (starting with c.1)

1	ggaaggcaat	taaggcgccc	atttcagaag	agtracagcc	gtgaaaatta	ctcagcagtg
61	cagttggctg	agaagaggaa	aaaaggtcag	aatgagagcg	ctcgctgtgc	tgtctgtcac
121	gctggttatg	gcctgcacag	aagccttctt	ccccttcatc	tcgagaggga	aagaactcct
181	ttggggaaag	cctgaggagt	ctcgtgtctc	tagcgtcttg	gaggaaagca	agcgcctggt
241	ggacaccgcc	atgtacgcca	cgatgcagag	aaacctcaag	aaaagaggaa	tcctttctcc
301	agctcagctt	ctgtcttttt	ccaaacttcc	tgagccaaca	agcggagtga	ttgcccgagc
361	agcagagata	atggaaacat	caatacaagc	gatgaaaaga	aaagtcaacc	tgaaaactca
421	acaatcacag	catccaacgg	atgctttatc	agaagatctg	ctgagcatca	ttgcaaacat
481	gtctggatgt	ctcccttaca	tgctgccccc	aaaatgccca	aacacttgcc	tggcgaacaa
541	atacaggccc	atcacaggag	cttgcaacaa	cagagaccac	cccagatggg	gcgcctccaa
601	cacggccctg	gcacgatggc	tccctccagt	ctatgaggac	ggcttcagtc	agccccgagg
661	ctggaacccc	ggcttcttgt	acaacgggtt	cccactgccc	ccggtccggg	aggtgacaag
/21	acatgtcatt	caagtttcaa	atgaggttgt	cacagatgat	gaccgctatt	ctgacctcct
/81	gatggcatgg	ggacaataca	tcgaccacga	catcgcgttc	acaccacaga	gcaccagcaa
841	agctgccttc	ggggggagggg	ctgactgcca	gatgacttgt	gagaaccaaa	acccatgttt
901	tcccatacaa	ctcccggagg	aggcccggcc	ggccgcgggc	accgcctgtc	tgcccttcta
1001	ccgctcttcg	gccgcctgcg	gcaccgggga	ccaaggcgcg	ctctttggga	acctgtccac
1021	ggccaacccg	cggcagcaga	tgaacgggtt	gacctcgttc	ctggacgcgt	ccaccgtgta
1141	tggcagctcc	ccggccctag	agaggcagct	gcggaactgg	accagegeeg	aagggctgct
1201	ccgcgcccac	gcgcgccccc	gggactccgg	ccgcgcctac	clyccclcg	Lgccgccacg
1201	cgcgcccgcg	geergegege	ccgageeegg	carcecegga	gagacccgcg	ggccccgccc
1201	actacacaca	gacggccgcg	taaccacaac	acterage	acggcactgc	acacycryry
1281	gergegegag	taccaddadd	cacacacaget	catagacact	ctacaccada	tcatcaccet
1//1	ggacgccgcg	atccccada	tectaaage	casaacette	cagcagtaga	tagateceta
1501	tasagactat	actecagga	ccaaccccac	tatatccaac	atatteteea	cancencett
1561	ccacttcaac	catoccacoa	tecaccodet	antaganagan	ctonacocca	acttocadda
1621	acaccccaac	ctacccaaac	tataactaca	ccannettte	ttcancccat	gacattact
1681	ccatagaaaat	aatttagacc	cactaataco	annocttett	ocaagaccag	ccaaactoca
1741	ootocaodat	canctoatoa	acqaqqaqct	gacggaaaagg	ctctttatac	totccaattc
1801	cagcaccttg	gatctggcgt	ccatcaacct	acaaaaaaaaaa	coooaccaco	ggctgccagg
1861	ttacaatgag	togaggagt	tctacaacct	acctcaccta	gagacccccg	ctgacctgag
1921	cacagccatc	accaacaada	acataaccaa	caagatcctg	gacttotaca	agcatcctga
1981	caacatcgat	atctaactaa	gaggettage	tgaaaacttc	ctccccaggg	ctcqqacaqq
2041	gcccctgttt	gcctgtctca	ttgggaagca	gatgaagget	ctgcgggacg	qtqactqqtt
2101	ttggtgggag	aacagccacg	tcttcacqqa	tgcacagagg	cgtgagctgg	agaagcactc
2161	cctgtctcgg	gtcatctgtg	acaacactgg	cctcaccagg	gtgcccatgg	atgccttcca
2221	agtcggcaaa	ttccccgaag	actttgagtc	ttgtgacagc	atcactggca	tgaacctgga
2281	ggcctggagg	gaaacctttc	ctcaagacga	caagtgtggc	ttcccagaga	gcgtggagaa
2341	tggggacttt	gtgcactgtg	aggagtctgg	gaggcgcgtg	ctggtgtatt	cctgccggca
2401	cgggtatgag	ctccaaggcc	gggagcagct	cacttgcacc	caggaaggat	gggatttcca
2461	gcctcccctc	tgcaaagatg	tgaacgagtg	tgcagacggt	gcccaccccc	cctgccacgc
2521	ctctgcgagg	tgcagaaaca	ccaaaggcgg	cttccagtgt	ctctgcgcgg	acccctacga
2581	gttaggagac	gatgggagaa	cctgcgtaga	ctccgggagg	ctccctcggg	tgacttggat
2641	ctccatgtcg	ctggctgctc	tgctgatcgg	aggettegea	ggtctcacct	cgacggtgat
2/01	ttgcaggtgg	acacgcactg	gcactaaatc	cacactgccc	atctcggaga	caggcggagg
2/61	aactcccgag	ctgagatgcg	gaaagcacca	ggccgtaggg	acctcaccgc	agcgggccgc
2821	ageteaggae	LCggagcagg	agagtgctgg	gatggaaggc	cgggatactc	acaggetgee
2881	gagagccctc	rgagggcaaa	gcggcaggac	actgcagaac	agetteatgt	LCCCAAAATC
2941	accycacgac	LCLLLLCCAA	acacaggcaa	accegaaate	agcaggacga	
2061	aacacgggta	tatctagtac	tatgicgtag	acattaceta	gcatggatga	acadatgtta
21 21	tageigeatt	atatatt	agattagaaa	acaligeerg	attigtteet	rerggggett
2121	ryccallada	acycattiac	ayalldaddd	ad		

stop codon (ending with c.2802)

2) Human thyroid peroxidase (TPO), isoform 1, protein (Uniprot Reference Sequence: P07202-1)

20 30 MRALAVLSVT LVMACTEAFF PFISRGKELL WGKPEESRVS SVLEESKRLV DTAMYATMQR NLKKRGILSP AQLLSFSKLP EPTSGVIARA AEIMETSIQA MKRKVNLKTQ QSQHPTDALS EDLLSIIANM SGCLPYMLPP KCPNTCLANK YRPITGACNN RDHPRWGASN TALARWLPPV YEDGFSQPRG WNPGFLYNGF PLPPVREVTR HVIQVSNEVV TDDDRYSDLL MAWGQYIDHD IAFTPQSTSK AAFGGGADCQ MTCENQNPCF PIQLPEEARP AAGTACLPFY RSSAACGTGD QGALFGNLST ANPRQQMNGL TSFLDASTVY GSSPALERQL RNWTSAEGLL RVHARLRDSG RAYLPFVPPR APAACAPEPG IPGETRGPCF LAGDGRASEV PSLTALHTLW LREHNRLAAA LKALNAHWSA DAVYQEARKV VGALHQIITL RDYIPRILGP EAFQQYVGPY EGYDSTANPT VSNVFSTAAF RFGHATIHPL VRRLDASFQE HPDLPGLWLH QAFFSPWTLL RGGGLDPLIR GLLARPAKLQ VQDQLMNEEL TERLFVLSNS STLDLASINL QRGRDHGLPG YNEWREFCGL PRLETPADLS TAIASRSVAD KILDLYKHPD NIDVWLGGLA ENFLPRARTG PLFACLIGKQ MKALRDGDWF WWENSHVFTD AQRRELEKHS LSRVICDNTG LTRVPMDAFQ VGKFPEDFES CDSITGMNLE AWRETFPQDD KCGFPESVEN GDFVHCEESG RRVLVYSCRH GYELQGREQL TCTQEGWDFQ PPLCKDVNEC ADGAHPPCHA SARCRNTKGG FQCLCADPYE LGDDGRTCVD SGRLPRVTWI SMSLAALLIG GFAGLTSTVI CRWTRTGTKS TLPISETGGG TPELRCGKHQ AVGTSPQRAA AQDSEQESAG MEGRDTHRLP RAL

3) Human thyroid peroxidase (TPO), RefSeqGene on chromosome 2 (NCBI

Reference Sequence: NG 011581.1, selected region from 4799 to 5949)

c.1-982

					200200 2002000 200	
1	cagaggctgg	actgcatgtg	gaccccgatg	acatggcact	ttgtttdtga	ccagtcagga
61	cacacaagag	gcccggcgca	aacacaacaa	agcccgcaga	cattctgtcc	ccacgaagaa
121	cggacgccac	tcgacttcct	agcatcttga	cgggctatcc	aagcgcggag	tcagtttata
181	aggtgggtaa	ccaagtccct	ggaaggcaat	taaggcgccc	atttcagaag	agttacagcc
241	gtgaaaatta	ctcagcagtg	cagttggctg	agaagaggaa	aaaaggtcag	gttgtaaagc
301	tttttatttt	tccattttct	aagagaaatt	catcattgga	acttgtaaag	tggcccaaga
361	gtggctgtaa	tttgggccat	tatagcaggt	atgggtggcg	tctctcagca	aagctgactg
421	actgactgat	gagtgctgtt	tgcaatgacc	tccgctggaa	catgtgagtc	ctgtagggtc
481	gattcctaga	tcaccgtcta	ctgagacaca	ttcctgtcag	catggactca	ctggtgctat
541	cctgcttaac	aaaattagtg	gctcaaaaat	agccacagaa	agcctaagag	aagaaaacaa
601	ggatttgaaa	gtagaaatga	tgaattttga	atcttctgtt	ttgtcttaac	aactagaatt
661	ctaaaatcat	tttatggaca	taagaatgct	ttaagaaatt	caataggcat	ttaggggttt
721	tatttatcac	ttttataaag	actaaatttc	taatagtact	cactttttgc	cacatagatg
781	cattagggga	aacagatttt	tttcattccc	aataattatt	cccagtactg	ttacactatt
841	tgacattacc	aaaaatttaa	ataggttatt	actgagatat	attggcaact	ggagctgcca
901	acataaaaac	tctgtttttg	aataatgggg	gcctgggagg	cctgctcagc	gctgcagttt
961	ctgtaacctc	ctgacatgga	cggcgactct	ggtctcgcag	accccaggcc	tgtgagggtc
1021	gctcactgcg	gtagaggctg	cgtggagtca	gtggagggag	cccctcagca	gggagacaag
1081	gacacagcgg	ttcccatggc	cttgtcagtg	cttgattaca	tactctgtct	ccttccgtta
1141	attttagaat	g	1999-0420-9420-201-420	Respectively and the second second second	envirus na c os deste	Randa ana ang ang ang ang ang ang ang ang an
	100	050				

c.1 (exon 2)

4) Human thyroid peroxidase (TPO), RefSeqGene on chromosome 2 (NCBI

Reference Sequence: NG 011581.1, selected region from 24969 to 25146)

c.180-6 c.180 (exon 4) 1 gccatagaaa cctcaagaaa agaggaatcc tttctccagc tcagcttctg tctttttcca 61 aactteetga gecaacaage ggagtgattg eeegageage agagataatg gaaacateaa 121 tacaagegat gaaaagaaaa gteaacetga aaacteaaca ateacageat eeaaegg

5) Human thyroid peroxidase (TPO), RefSeqGene on chromosome 2 (NCBI

Reference Sequence: NG 011581.1, selected region from 87993 to 88308)

c.2216 (exon 13) c.2216-34

301 cctctgcaaa ggtcag

APPENDIX D

Recipe for stock solutions and general use buffers

1) Preparation of 50 X Tris-acetate-EDTA (TAE) buffer

For 1 L of 50 X TAE buffer, 40 mM tris base, 20 mM glacial acetic acid and 2 mM EDTA were mixed and the total volume was made up to 1 L with double distilled water. For agarose gel electrophoresis, the working concentration of 1X TAE buffer was used.

2) Preparation of 6 X Laemmli buffer

For 10 ml of 6 X Laemmli buffer, 1.2 g of SDS, 6 mg of bromophenol blue, 4.7 ml of glycerol, 1.2 ml of Tris 0.5 M pH 6.8 and 2.1 ml of ddH₂O were mixed and warmed until everything was dissolved. About 0.93 g of DTT was then added and completely dissolved in the buffer. The prepared buffer was aliquoted for several smaller tubes and stored at -20 \mathbb{C} .

3) Preparation of 10 X SDS-PAGE running buffer

To prepare 10 X SDS-PAGE running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS), 288g of glycine and 60.4 g of Tris base were dissolved in 1.8 L of ddH_2O . Twenty gram of SDS was then added and mixed into the solution. Finally, additional ddH2O was added to a final volume of 2 L.

4) Preparation of Coomassie stain

To prepare 200 ml of Coomassie blue stain (50 % MeOH, 10 % acetic acid, 0.05% Brillaint Blue R-250), 0.1 g of Brilliant Blue R-250 was first dissolved in 100 ml of MeOH. Twenty milliliter of acetic acid was then added to the solution. Finally, 80 ml of ddH2O was added to a final volume of 200 ml.

5) Preparation of 1 X Tris-glycine buffer

To prepare 2 L of 1 X Tris-glycine buffer (25 mM Tris, 192 mM glycine, 10 % methanol), 28.8 g of glycine and 6.04 g of Tris base was first dissolved in 1.6 L of ddH2O. Two hundred milliliter of MeOH was then added to the solution. Finally, additional ddH2O was added to a final volume of 2 L.

APPENDIX E



Exon-exon boundary for all exons of the TPO variants

Figure 1 Electropherograms showing exon-exon boundary for all exons (except exon 12 to exon 13 which had been shown in Figure 4.60) of TPO1 of the CHP33.



Figure 1 Continued.

Electropherogram	Forward(F) / Reverse(R) sequencing	Exon-exon boundary	ТРО
A C C A N C T C C A	R	10/9	1
$\begin{bmatrix} 160 \text{ Exon } 10 \\ G & C & C \end{bmatrix} = \begin{bmatrix} 160 \text{ Exon } 10 \\ G & T & T \end{bmatrix} = \begin{bmatrix} 160 \text{ Exon } 11 \\ C & C & C \end{bmatrix}$	F	10/11	1
	F	11/12	1
$ \begin{array}{c c} Exon 14 \\ C & C & T \\ \hline C & C & T \\ \hline C & T \\ $	R	14/13	1

Figure 1 Continued.



Figure 1 Continued.



Figure 2 Electropherograms showing exon-exon boundary for a) exons 9/11 in TPO2, b) exon 13/15 in TPO4 and c) exons 15/17 in TPO3 of the CHP33.

APPENDIX F





Figure 1 A standard curve of protein concentration versus absorbance at 595 nm. Bovine serum albumin (BSA) protein standard solution at a range of 0 mg/ml to 10.0 mg/ml was used. From the calibration curve, the protein concentration of the microsomal fraction extracts was to be estimated in the range of 1.12 μ g/ μ l to 3.12 μ g/ μ l.

APPENDIX G

The expression level of TPO protein in:

1) CHP33 (III-2)

Experiment	Protein band density	Expression	
i	Normal Area	RelativeAdjustmentDensityDensity	
Normal Lesion area area TPO	β-actin TPO 12.84 98.87 40.89	TPO/β- actin = 12.84/38.8 =0.33 lesion area / normal area = 0.19/0.33 X	
β-actin	area β-actin TPO	$\begin{array}{c} \text{TPO}/\beta-\\ \text{actin} =\\ 7.81/40.68\\ =0.19 \end{array} $	
ii Normal Lesion area area TPO	Normal area β-actin TPO 583 48,85	$\begin{array}{c} TPO/\beta-\\ actin =\\ 5.63/48.85\\ =0.12\\ \end{array}$ $\begin{array}{c} lesion area /\\ normal area =\\ 0.09/0.12 \text{ X} \end{array}$	
β-actin	area β-actin TPO	TPO/β- actin = 3.76/43.76 =0.09	

Experiment		Protein band density	Exp	Expression	
iii			Relative	Adjustment	
		Normal	Density	Density	
Normal Lesion area area Τ	FPO 3-actin	Normal area β-actin TPO 428 Lesion	TPO/β- actin = 6.87/44.28 =0.16	lesion area / normal area = 0.14/0.16 X	
		area β-actin TPO	TPO/β- actin = 6.16/43.72 =0.14	87.5%	
iv Normal Lesion area area β	TPO 3-actin	Normal area β-actin TPO 17.08 Lesion area	TPO/β- actin = 17.08/38.4 =0.44 TPO/β- actin = 11.22/33.3	lesion area / normal area = 0.34/0.44 X 100% = 77.27%	
in one distribution democratical and difficult		β-actin TPO	=0.34		

Experiment	lesion area/normal area Up-regulation if >100% ; Down-regulation of <100%	Expression (fold change)	Average
i	57.58%	1.74	1.26 ± 0.26 fold
ii	75%	1.33	1.50±0.20 1010
iii	87.5%	1.14	(uowii regulation)
iv	77.27	1.29	regulation)

2) CHP33's sister (III-1)

Experiment	Protein band density	Expression	
i	Normal	Relative Adjustment	
Normal Lesion area area TPO	area β-actin TPO 6.39	DensityDensityTPO/ β - actin = 5.39/51.15 = 0.11lesion area / normal area =	
β-actin	Lesion area β-actin TPO	0.05/0.11 X 100% = 45.45% TPO/β- actin = 2.13/41.33 =0.05	
ii Normal Lesion area area TPO	Normal area β-actin TPO 54.03	$\begin{array}{c} \text{TPO}/\beta-\\ \text{actin} =\\ 7.09/54.83\\ =0.13\\ \hline \\ \text{normal area} =\\ 0.05/0.13 \text{ X} \end{array}$	
β-actin	Lesion area β-actin 1.87PO	100% = 38.46% TPO/β- actin = 1.87/37.01 =0.05	

Experiment	Protein band density	Exp	ression
iii		Relative	Adjustment
		Density	Density
Normal Lesion area area TPO β-actin	Normal area β-actin TPO 437 Lesion area β-actin TPO 220	TPO/ β - actin = 4.79/55.78 =0.09 TPO/ β - actin = 2.0/37.43 =0.05	lesion area / normal area = 0.05/0.09 X 100% = 55.56%

Experiment	lesion area/normal area Up-regulation if >100% ; Down- regulation of <100%	Expression (fold change)	Average
i	45.45%	2.2	2.2±0.4
ii	38.46%	2.6	(down
iii	55.56%	1.8	regulation)

Experiment	Protein band density	Exp	ression
i		Relative	Adjustment
	III-1 (CHP33's sister) B-actin A	Density	Density
III-1 CHP33 TPO β-actin	TPO 1.80 CHP33 β-actin	TPO/β- actin = 1.80/41.89 =0.04	III-1/CHP33 = 0.04/0.28 X 100% = 14.29%
	43.92 12.38	actin =12.38/43. 92 = 0.28	
ii II-1 CHP33	III-1 (CHP33's sister) β-actin	TPO/β- actin = 0.6/39.82 =0.02	III-1/CHP33 = 0.02/0.13 X 100% =
β-actin	CHP33 β-actin	TPO/β- actin =7.01/52.5 7 = 0.13	15.38%

Experiment	Thyroid lesion/normal tissue Up-regulation if >100% ; Down- regulation of <100%	Expression (fold change)	Average
i	14.29%	7	6.75±0.35 fold (down
ii	15.38%	6.5	regulation)

APPENDIX H

Multiple sequence alignment of amino acids in human TPO with rat TPO



Figure 1 Multiple sequence alignment of amino acids in human TPO with rat TPO showing full conservation of all residues that located within the epitope for Moab47 (residues 713 to 721) except Glu-716.

APPENDIX I



JAWATANKUASA ETIKA PERUBATAN PUSAT PERUBATAN UNIVERSITI MALAYA

ALAMAT: LEMBAH PANTAI, 59100 KUALA LUMPUR, MALAYSIA TELEFON: 03-79494422 FAKSIMILI: 03-79545682

AME OF ETHICS COMMITTEE/IRB:	ETHICS
vicultar Eules Commutee, Oniversity Maraya Medicar Centre	COMMITTEE/IRB REFERENCE NUMBED
ADDRESS: LEMBAH PANTAI	REPERENCE NOMBER
59100 KUALA LUMPUR	654.16
PROTOCOL NO:	
Disorders	Congenital Endocrine
PRINCIPAL INVESTIGATOR: Dr. Sarni Mat Junit	SPONSOR:
TELEPHONE: KOMTEL:	26- APPLICATION FOR AN EXTENSION
The following item $[\checkmark]$ have been received and reviewed in connection investigator	with the above study to be conducted by the above
y Borang Permohonan Penyelidikan	Ver date: 2 May 08
[] Study Protocol	Ver date:
Investigator Diochure Investigator Diochure	Ver date:
[V] Consent Form	Ver date:
	ver date:
[] Investigator(s) CV's (Dr. Sarni Mat Junit)	
and have been [1]	
 Conditionally approved (identify item and specify modification be Rejected (identify item and specify reasons below or in accompan 	low or in accompanying letter) ying letter)
Comments:	
in hundrand burdes	
Please field attached the proping and sectors in the	
i. Investigator is required to follow instructions, guidelines and	requirements of the Medical Ethics Committee.
<i>ii.</i> Investigator is required to report any protocol deviations/viol provide annual/closure reports to the Medical Ethics Commit	ations through the Clinical Investigation Centre and tee.
Date of approval: 28 th May 2008	
s.k Ketua	
Jabatan Perubatan Molekul	

Timbalan Dekan (Penyelidikan) Fakulti Perubatan, Universiti Malaya

Setiausaha Jawatankuasa Penyelidikan Pusat Perubatan Fakulti Perubatan, Universiti Malaya PROF. LOOI LAI MENG Chairman Medical Ethics Committee

APPENDIX J

Consent by patient for clinical research University of Malaya Medical Centre, K.L.

I, Name of Patien	Identity Card No at)	
of	(Address)	
hereby agree to take part in the below:	e clinical research (clinical study/questio	nnaire study/drug trial) specified
<u>Title of Study:</u>		
the nature and purpose of which h	nas been explained to me by Dr (Name	e & Designation of Doctor)
	and interpreted by	
	(Name & Desi	gnation of Interpreter)
I have been told about the nature	to the best of his/her ability in	language/dialect
I have been told about the nature and complications (as per patien advantages and disadvantages of 1 in the clinical research specified ak I understand that I can withdra whatsoever and in such a situati doctors.	to the best of his/her ability in e of the clinical research in terms of met it information sheet). After knowing a this clinical research, I voluntarily consen pove. av from this clinical research at any th ion shall not be denied the benefits of	language/dialect hodology, possible adverse effect nd understanding all the possibl t of my own free will to participat me without assigning any reaso usual treatment by the attendin
t I have been told about the nature and complications (as per patien advantages and disadvantages of t in the clinical research specified ab I understand that I can withdra whatsoever and in such a situati doctors. Date:	to the best of his/her ability in e of the clinical research in terms of met it information sheet). After knowing a this clinical research, I voluntarily consen- pove. w from this clinical research at any ti- ion shall not be denied the benefits of Signature or Thumbprint	language/dialect hodology, possible adverse effect ad understanding all the possible t of my own free will to participate me without assigning any reason usual treatment by the attending
I have been told about the nature and complications (as per patien advantages and disadvantages of 1 in the clinical research specified ak I understand that I can withdra whatsoever and in such a situati doctors. Date:	to the best of his/her ability in e of the clinical research in terms of met it information sheet). After knowing a this clinical research, I voluntarily consen pove. w from this clinical research at any ti ion shall not be denied the benefits of Signature or Thumbprint	language/dialect hodology, possible adverse effect ad understanding all the possibl t of my own free will to participat me without assigning any reaso usual treatment by the attendin (Patient)
t I have been told about the nature and complications (as per patien advantages and disadvantages of t in the clinical research specified ah I understand that I can withdra whatsoever and in such a situati doctors. Date:	to the best of his/her ability in e of the clinical research in terms of met it information sheet). After knowing a this clinical research, I voluntarily consen- pove. w from this clinical research at any ti ion shall not be denied the benefits of Signature or Thumbprint IN THE PRESENCE OF	language/dialect hodology, possible adverse effect ad understanding all the possible t of my own free will to participate me without assigning any reason usual treatment by the attendin (Patient)
I have been told about the nature and complications (as per patien advantages and disadvantages of 1 in the clinical research specified ak I understand that I can withdra whatsoever and in such a situati doctors. Date:	to the best of his/her ability in e of the clinical research in terms of met it information sheet). After knowing an this clinical research, I voluntarily consen- pove. aw from this clinical research at any the ion shall not be denied the benefits of Signature or Thumbprint IN THE PRESENCE OF	language/dialect hodology, possible adverse effect ad understanding all the possible t of my own free will to participat me without assigning any reason usual treatment by the attendin (Patient)
t I have been told about the nature and complications (as per patien advantages and disadvantages of t in the clinical research specified ah I understand that I can withdra whatsoever and in such a situati doctors. Date: Name Name	to the best of his/her ability in e of the clinical research in terms of met it information sheet). After knowing as this clinical research, I voluntarily consen- bove. we from this clinical research at any the ion shall not be denied the benefits of Signature or Thumbprint IN THE PRESENCE OF))) Signature	language/dialect hodology, possible adverse effect ad understanding all the possible t of my own free will to participate me without assigning any reason usual treatment by the attendin (Patient)
I have been told about the nature and complications (as per patien advantages and disadvantages of 1 in the clinical research specified ak I understand that I can withdra whatsoever and in such a situati doctors. Date: Name Identity Card No. Designation	to the best of his/her ability in e of the clinical research in terms of met it information sheet). After knowing an this clinical research, I voluntarily consen- pove. aw from this clinical research at any the ion shall not be denied the benefits of Signature or Thumbprint IN THE PRESENCE OF))) Signature	language/dialect hodology, possible adverse effect ad understanding all the possible t of my own free will to participate me without assigning any reason usual treatment by the attending (Patient) (Patient)
t I have been told about the nature and complications (as per patien advantages and disadvantages of i in the clinical research specified ab I understand that I can withdra whatsoever and in such a situati doctors. Date: Name Identity Card No. Designation I confirm that I have explained to t	to the best of his/her ability in e of the clinical research in terms of met it information sheet). After knowing an this clinical research, I voluntarily consen- pove. w from this clinical research at any the ion shall not be denied the benefits of Signature or Thumbprint IN THE PRESENCE OF)) Signature	language/dialect hodology, possible adverse effect ad understanding all the possible t of my own free will to participate me without assigning any reason usual treatment by the attending (Patient) Witness for Signature of Patient) above-mentioned clinical research

CONSENT BY PATIENT FOR CLINICAL RESEARCH FPU-DOF-8K-012-05-R01 R.N. Name Sex Age Unit

Consent by responsible relative for clinical research

I,		Identity Card N	o
(Name,)	1999 N.T. 1977 N. 1978 N. 1978 N. 1978	
of	(Advase)		
	(Address)		
hereby agree that my relative	(Nama)		LC. No
participate in the clinical research (clin <u>Title of Study:</u>	uvanie) nical study/questi	onnaire study/dru	g trial) specified below:-
the nature and purpose of which has h	peen explained to	me by Dr	
	aleja)	av	ame & Designation of Doctor)
and int	terpreted by	Alama & D	niou ation of but annuat as 1
		(warne & Di	signation of interpreter)
to the b	est of his/her abil	ity in	language/dialect.
I understand that I can withdraw my reason whatsoever and in such situati the attending doctors. Should my re remain in this research or may choose Rel	relative from thi ion, my relative s lative regains his to withdraw. ationship	s clinical research hall not be denied /her ability to cor	at any time without assigning any the benefits of usual treatment by isent, he/she will have the right to Signature or
Date: to	Patient		Thumbprint
	IN THE PRE	SENCE OF	
Name)		
Thereity Country)	6	
Identity Card No.)	Signature	(Witness)
Designation			
I confirm that I have explained to the p clinical research.	patient's relative t	he nature and pur	pose of the above-mentioned
Date	Signature	(Attending	Doctor)
CONSENT BY RESPONSIBLE RELATIVE F CLINICAL RESEARCH	R.N. Name OR Sex Age Unit		